DSDenis Sidorenko

Denis Sidorenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denis Sidorenko has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The End of Aging Clocks: Training Foundation Models to Reason in Aging and Longevity

    by Alex Zhavoronkov, Vladimir Aladinskyi, Alex Aliper, Zulfat Miftakhutdinov, Mathieu Reymond, Vladimir Naumov, Diana Zagirova, Stefan Pushkov, Denis Sidorenko, Rim Shayakhmetov, et al.

    The aging clock paradigm has yielded dozens of specialist models that can estimate chronological age or mortality from virtually any biodata type. Yet each such model operates within a fixed modality, relies on a predetermined feature set, and produces limited biological interpretation. Here, we report Longevity-LLM v0.1, a Qwen3-14B model fine-tuned through supervised and reinforcement learning regimes on DNA methylation, proteomics, clinical biomarker, and RNA expression data. Longevity-LLM achieves high ranks in the recently announced Longevity Bench, including such tasks as cancer survival and RNA- or proteome-based age prediction. After reinforcement fine-tuning, the model achieved a 4.34-year MAE in epigenetic age prediction, surpassing the Horvath multi-tissue clock. In addition to age prediction, Longevity-LLM can carry out numerous other tasks, including proteomic profile generation, for which it significantly outperforms all frontier LLMs. These results demonstrate that a single modestly sized LLM can match or replace purpose-built aging clocks across data modalities. This work constitutes an interim report from the initial sprint of our Multi-Modal AI Gym for Science (MMAI), an initiative dedicated to building foundation models for drug discovery and aging research.

  • Open Access

    LongevityBench: Are SotA LLMs ready for aging research?

    by Alex Zhavoronkov, Denis Sidorenko, Vladimir Naumov, Stefan Pushkov, Diana Zagirova, Vladimir Aladinskiy, Derya Unutmaz, Alex Aliper, Fedor Galkin

    Aging is a core biological process observed in most species and tissues, which is studied with a vast array of technologies. We argue that the abilities of AI systems to emulate aging and to accurately interpret biodata in its context are the key criteria to judge an LLM’s utility in biomedical research. Here, we present LongevityBench — a collection of tasks designed to assess whether foundation models grasp the fundamental principles of aging biology and can use low-level biodata to arrive at phenotype-level conclusions. The benchmark covers a variety of prediction targets including human time-to-death, mutations’ effect on lifespan, and age-dependent omics patterns. It spans all common biodata types used in longevity research: transcriptomes, DNA methylation profiles, proteomes, genomes, clinical blood tests and biometrics, as well as natural language annotations. After ranking state-of-the-art foundation models using LongevityBench, we highlight their weaknesses and outline procedures to maximize their utility in aging research and life sciences.

  • Open Access

    Precious2GPT: the combination of multiomics pretrained transformer and conditional diffusion for artificial multi-omics multi-species multi-tissue sample generation

    by Denis Sidorenko, Stefan Pushkov, Akhmed Sakip, Geoffrey Ho Duen Leung, Sarah Wing Yan Lok, Anatoly Urban, Diana Zagirova, Alexander Veviorskiy, Nina Tihonova, Aleksandr Kalashnikov, et al.

    Synthetic data generation in omics mimics real-world biological data, providing alternatives for training and evaluation of genomic analysis tools, controlling differential expression, and exploring data architecture. We previously developed Precious1GPT, a multimodal transformer trained on transcriptomic and methylation data, along with metadata, for predicting biological age and identifying dual-purpose therapeutic targets potentially implicated in aging and age-associated diseases. In this study, we introduce Precious2GPT, a multimodal architecture that integrates Conditional Diffusion (CDiffusion) and decoder-only Multi-omics Pretrained Transformer (MoPT) models trained on gene expression and DNA methylation data. Precious2GPT excels in synthetic data generation, outperforming Conditional Generative Adversarial Networks (CGANs), CDiffusion, and MoPT. We demonstrate that Precious2GPT is capable of generating representative synthetic data that captures tissue- and age-specific information from real transcriptomics and methylomics data. Notably, Precious2GPT surpasses other models in age prediction accuracy using the generated data, and it can generate data beyond 120 years of age. Furthermore, we showcase the potential of using this model in identifying gene signatures and potential therapeutic targets in a colorectal cancer case study.


  • Open Access

    Predicting gene-disease associations using a heterogeneous graph neural network

    by D.A. Sidorenko, Shalyto Anatoly A. Sidorenko Denis A.

    The research presents the development of a heterogeneous graph neural network model for predicting gene-disease using existing genomic and medical data. The novelty of the approach is in integrating the principles of graph neural networks and heterogeneous information networks for efficient processing of structured data and consideration of complex genepathology interactions. The solution proposed is a heterogeneous graph neural network which utilizes a heterogeneous graph structure for representing genes, diseases, and their relationships. The performance of the developed model was evaluated on the DisGeNET, LASTFM, YELP datasets. On these datasets, a comparison was made with current SOTA models. The comparison results demonstrated that the proposed model outperforms other models in terms of Average Precision (AP), F1-measure (F1@S), Hit@k, Area Under Receiver Operating Characteristic curve (AUROC) in predicting “gene-disease” associations. The model developed serves as a tool for bioinformatics analysis and can aid researchers and doctors in studying genetic diseases. This could expedite the discovery of new drug targets and the advancement of personalized medicine.

  • Open Access

    Precious3GPT: Multimodal Multi-Species Multi-Omics Multi-Tissue Transformer for Aging Research and Drug Discovery

    by Fedor Galkin, Vladimir Naumov, Stefan Pushkov, Denis Sidorenko, Anatoly Urban, Diana Zagirova, Khadija M. Alawi, Alex Aliper, Ruslan Gumerov, Aleksandr Kalashnikov, et al.

    We present a multimodal multi-species multi-omics multi-tissue transformer for aging research and drug discovery capable of performing multiple tasks such as age prediction across species, target discovery, tissue, sex, and disease sample classification, drug sensitivity prediction, replication of omics response and prediction of biological and phenotypic response to compound treatment. This model combines textual, tabular, and knowledge graph-derived representations of biological experiments to provide insights into molecular-level biological processes. We demonstrate that P3GPT has developed an intuition for the interactions between compounds, pathologies, and gene regulation in the context of multiple species and tissues. In these areas, it outperforms existing LLMs and we highlight its utility in diverse case studies. P3GPT is a general model that may be used as a target identification tool, aging clock, digital laboratory, and scientific assistant. The model is intended as a community resource available open source as well as via a Discord server.